scholarly journals Personalized medicine – a tailored health care system: challenges and opportunities

2012 ◽  
Vol 53 (3) ◽  
pp. 211-213 ◽  
Author(s):  
Soulla Louca
Author(s):  
Subhas C. Misra ◽  
Sandip Bisui ◽  
Kamel Fantazy

Among the emerging areas in health-care system, the implementation of Electronic Medical Record system and the discovery of Personalized Medicine are occupying top positions. While some of the personalized drugs have already been discovered, implementing this new medicare system requires a lot of changes in the traditional health-care system. This paper aims at identifying these critical changes required in the adoption of the Personalized Medicine system. A systemic attempt has been made to prepare a list of possible changes required for the adoption based on available literature. This research study shows that changes from reactive to efficient medical care, from trial and error to right treatment for right person at right time, from narrow mind-set to open mindedness, from open information of patients to secure information, from less emphasis on IT infrastructure to more emphasis on IT infrastructure are some of the significant changes that are necessary for implementing the revolutionary medicare system of personalized Medicine.


2020 ◽  
Author(s):  
Christina Shayevitz ◽  
Scott Breitinger ◽  
Mackenzie P. Lerario ◽  
Megan Mroczkowski ◽  
Martin Osuji ◽  
...  

2016 ◽  
Vol 6 (3) ◽  
pp. 18 ◽  
Author(s):  
Scott Weiss

Recently we at Partners Health Care had a series of articles in the Journal of Personalized Medicine describing how we are going about implementing Personalized Medicine in an academic health care system [1–10].[...]


2016 ◽  
Vol 22 (5) ◽  
pp. 602-611 ◽  
Author(s):  
Grace C. Haser ◽  
R. Michael Tuttle ◽  
Henry K. Su ◽  
Eran E. Alon ◽  
Donald Bergman ◽  
...  

2021 ◽  
pp. 1012-1023
Author(s):  
William Armando Mantilla ◽  
María Carolina Sanabria-Salas ◽  
Ana Margarita Baldion ◽  
Luz F. Sua ◽  
Diego Mauricio Gonzalez ◽  
...  

Given the benefits and likely future applications, there is an urgent need to expand the use of next-generation sequencing (NGS) in breast, lung, and unknown primary cancers in Colombia. The objective of this review is to address the barriers limiting access to the use of NGS in Colombia, specifically for patients with breast, lung, and unknown primary cancers in the public health care system. A selected Panel of Colombian experts in NGS were provided with a series of relevant questions to address in a multiday conference. Each narrative was discussed and edited by the Panel through numerous drafts and rounds of discussion until consensus was achieved. There are limitations to the widespread adoption of innovative technology inherent to the Colombian health care system. Barriers identified to implementing NGS in Colombia include availability, accessibility, and affordability; limited infrastructure; training and awareness of health personnel; quality-control procedures; and collection of local data. Stakeholders must align to adapt the implementation of NGS to the constraints of resource-limited environments. Diagnostic algorithms were developed to guide molecular testing for lung, breast, and unknown primary cancers. Recommendations on overcoming the barriers to the widespread adoption of NGS include country-specific molecular testing guidelines, creating a national genetic registry, improving infrastructure, and creating health policy that favors the adoption of innovative technology.


2016 ◽  
Vol 60 (2) ◽  
Author(s):  
CarloAlberto Redi

One of the main precision medicine’s promises is nutrigenomics; still far from being a widespread attitude for the laypeople, it is certainly one of the most challenging aspect of the near to come health care system based on personalized medicine. Thus, we welcome books like this one that is exploring the pre-requisites to get a better health care in the new millennium.....


2012 ◽  
Vol 30 (34) ◽  
pp. 4262-4266 ◽  
Author(s):  
Jeffrey S. Hoch ◽  
David C. Hodgson ◽  
Craig C. Earle

Recently, the evidence-based drug funding process in Ontario, Canada, was challenged by a young mother with a breast tumor too small, based on the evidence that existed at the time, to qualify for an expensive drug. In reality, this is only the latest in a number of challenges the publicly funded health care system has had to deal with in the face of an evolving drug policy landscape. This article defines comparative effectiveness research (CER), considering how it is viewed differently in the United States and Canada. It also reviews the role CER now plays in the Ontario drug funding process and concludes with a review of the challenges and opportunities of using observational data to conduct CER and incorporate it into policy making within a universal health care system. Many of the issues faced by Ontario are relevant beyond Canada, including in the United States during this period of health care reform.


Sign in / Sign up

Export Citation Format

Share Document